Immunotherapy is regarded as the most promising treatment for cancers. Various cancer
immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies …

For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …

Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies. Despite its
undeniable therapeutic value, we still do not fully understand the mechanisms of action …

Macrophages are innate immune cells that derive from circulating monocytes, reside in all
tissues, and participate in many states of pathology. Macrophages play a dichotomous role …

CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but
not stem or plasma cells. It is an ideal target for monoclonal antibodies (mAb), such as …

The therapeutic utility of antibodies and their derivatives is achieved by various means. The
FDA has approved several targeted antibodies that disrupt signaling of various growth factor …

Rituximab is a human/murine chimeric monoclonal antibody primarily used for treating non-
Hodgkin's B-cell lymphoma. Recently it has also been used in the treatment of several …

Because macrophages have been implicated as major players in the mechanism of action of
rituximab, we have investigated the factors that modulate their tumor cell killing potential …

Abstract The CD20 mAb ofatumumab (OFA) is more effective than rituximab (RTX) in
promoting complement-dependent cytotoxicity (CDC) of B cells via the classical pathway …

Purpose High amounts of intratumoral macrophages have been shown to correlate with
poor prognosis in patients with follicular lymphoma (FL) treated with chemotherapy without …